Abstract
Neurological Immune Related Adverse Events (irAEs) secondary to Immune Checkpoint Inhibitors (ICI) are unncommon with an incidence of 1% to 5%. Among them, the Guillain Barré syndrome may be life-threatening and must be diagnosed early. We describe a clinical case of Guillain Barré Syndrom with a concomitant Campylobacter Jejuni colitis occurring after the first intravenous injection of pembrolizumab. A review of literature regarding the Guillain Barré syndrome after ICI use is added as a complementary source.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
